US asthma prophylaxis approval revives Acton's interest in Aerospan alliances
This article was originally published in Scrip
Acton Pharmaceuticals, a private US company that specialises in getting difficult new inhaled drug formulations onto the market, won its first supplemental new drug application (sNDA) approval from the US FDA for Aerospan (flunisolide HFA, 80mcg) Inhalation Aerosol as a prophylactic asthma maintenance therapy for adult and paediatric patients aged six and older.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.